Inventor · disambiguated record
William Pierceall
Also filed as: PIERCEALL WILLIAM · PIERCEALL WILLIAM E · PIERCEALL WILLIAM EDWARD
9 granted patents·12 pending applications·359 citations·filing 1999–2025
88Inventor score
Files withCELGENE CORP5EUTROPICS PHARMACEUTICALS INC4EXACT SCIENCES CORP4ORYZON GENOMICS SA3BRISTOL MYERS SQUIBB CO1
Top patents by PatentIndex Score
21 records- 0195US6503718B2Methods for detecting mutations using primer extension for detecting diseaseEXACT SCIENCES CORP·Filed 2001·Granted Jan 7, 2003·144 cites·19 claims
- 0295US6475738B2Methods for detecting mutations using primer extension for detecting diseaseEXACT SCIENCES CORP·Filed 2001·Granted Nov 5, 2002·91 cites·13 claims
- 0391US6482595B2Methods for detecting mutations using primer extensionEXACT SCIENCES CORP·Filed 2001·Granted Nov 19, 2002·48 cites·18 claims
- 0481US6280947B1Methods for detecting nucleotide insertion or deletion using primer extensionEXACT SCIENCES CORP·Filed 1999·Granted Aug 28, 2001·72 cites·12 claims
- 0578US12396995B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Aug 26, 2025·0 cites·34 claims
- 0678US2025352551A1Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2025·Application pending·0 cites
- 0775US10265279B2Combinations of LSD1 inhibitors for use in the treatment of solid tumorsORYZON GENOMICS SA·Filed 2017·Granted Apr 23, 2019·4 cites·14 claims
- 0868US11583536B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted Feb 21, 2023·0 cites·41 claims
- 0960US11519015B2Methods for determining chemosensitivity and chemotoxicityEUTROPICS PHARMACEUTICALS INC·Filed 2020·Granted Dec 6, 2022·0 cites·19 claims
- 1057US2024228667A9Methods for Treating Multiple MyelomaCELGENE CORP·Filed 2022·Application pending·0 cites
- 1157US2018246106A1Surrogate functional diagnostics test for cancerEUTROPICS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1255US2015301053A1Surrogate functional diagnostics test for cancerEUTROPICS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1353US10640803B2Methods for determining chemosensitivity and chemotoxicityEUTROPICS PHARMACEUTICALS INC·Filed 2014·Granted May 5, 2020·0 cites·14 claims
- 1453US2023172923A1Methods of treating cytokine-related adverse eventsBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1547US2023364230A1Combination therapy for cancerENGMAB SARL·Filed 2021·Application pending·0 cites
- 1647US2023255975A1Methods for treating cancer with combination therapiesCELGENE CORP·Filed 2021·Application pending·0 cites
- 1744US2008096903A1Sulfamoyl-containing derivatives and uses thereofWYETH CORP·Filed 2007·Application pending·0 cites
- 1841US2011217713A1Biomarkers For The Identification, Monitoring, And Treatment Of Non-Small Cell Lung Cancer (NSCLC)ON Q ITY·Filed 2011·Application pending·0 cites
- 1932US2019153538A1Gene expression biomarkers for personalized cancer care to epigenetic modifying agentsORYZON GENOMICS SA·Filed 2016·Application pending·0 cites
- 2032US2019256929A1Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agentsORYZON GENOMICS SA·Filed 2017·Application pending·0 cites
- 2130US2017227544A1Methods for personalizing patient cancer therapy with an mdm2 antagonistHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William Pierceall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →